GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors
- Dr. Goldberg Brings Perspective as Medical Oncologist and Hematologist and Extensive Biopharmaceutical Regulatory Experience to GlycoMimetics Board -
"A seasoned oncologist, hematologist and corporate medical/regulatory
strategist, Mark is a welcome addition to the GlycoMimetics Board of
Directors," said
Dr. Goldberg joined Synageva in 2011 from Genzyme Corporation, where he
had most recently served as Senior Vice President, Clinical Development
and Global Therapeutic Group Head,
"I'm excited about the opportunity to join the GlycoMimetics Board of Directors," said Dr. Goldberg. "As an oncologist and hematologist, it's encouraging to see a biotechnology company developing novel drug candidates for unmet medical needs such as sickle cell disease and many forms of cancer."
About
Cautionary Note on Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for
bhahn@glycomimetics.com
Source:
News Provided by Acquire Media